Recovery of and uses of specific binding agents

• US 5,989,926 A
• Filed: 10/22/1997
• Issued: 11/23/1999
• Est. Priority Date: 11/24/1994
• Status: Expired due to Term

• Current Assignee: Inverness Medical Switzerland GmbH (Abbott Laboratories Incorporated)
• Original Assignee: Unipath Limited (Abbott Laboratories Incorporated)
• Inventors: Wattam, Trevor, Berry, Mark J, Badley, Robert A, Porter, Philip
• Primary Examiner(s): Housel, James C.
• Assistant Examiner(s): NGUYEN, BAO THUY L
• Application Number:
  US08/955,723
• Time in Patent Office: 762 Days
• Field of Search: 435/7.1, 435/7.95, 435/961, 436/507, 436/510, 436/512, 436/518, 436/541, 436/547, 436/8, 436/16, 530/389.2
• US Class Current: 436/538
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/743 Steroid hormones
• CPC Class Codes: Y10S 435/961 including a step of forming, releasing, or exposing the antigen or forming the hapten-immunogenic carrier complex or the antigen per se
• CPC Class Codes: Y10T 436/10 Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
• CPC Class Codes: Y10T 436/106664 Blood serum or blood plasma standard or control

Abstract

An antibody specific for a target analyte is purified by affinity chromatography on a substrate bearing a low-affinity analogue of the target analyte. The antibody is displaced from the substrate by contact with a second analogue of intermediate affinity, which remains complexed with the antibody. This complex can be used in a conventional assay for the target analyte, which displaces the intermediate-affinity analogue. The complexed antibody is rendered more storage-stable because the second analogue protects the antibody binding reagion.

Claims

1. A process for recovering a specific binding agent possessing high affinity for a target ligand which comprises:

(a) contacting a first medium containing the specific binding agent with a solid phase having immobilized thereon a first analogue of the target ligand, said specific binding agent possessing comparatively low affinity for said first analogue when compared with the affinity of said binding agent to the target ligand or a second analogue of said target ligand;

(b) separating the solid phase from said first medium;

(c) then contacting said solid phase with a second medium containing said second analogue of the target ligand, said specific binding agent possessing an intermediate affinity for said second analogue which is greater than the affinity of said first analogue for said binding agent but less than the affinity of said target ligand for said binding agent, whereby specific binding agent which has become bound to said solid phase is preferentially bound to said second analogue and thereby released from said solid phase in the form of a complex with said second analogue and subsequently displacing said second analogue from said complex by exposure of said complex to said target ligand wherein the specific binding agent preferentially binds to said target ligand.

2. A process according to claim 1, wherein the affinity of said specific binding agent for said target ligand is at least about 5 times greater than its affinity for said first analogue.

3. A process according to claim 2, wherein the affinity of said specific binding agent for said target ligand is at least about 5 times greater than its affinity for said second analogue.

4. A process according to claim 1, wherein said specific binding agent is an antibody or antibody fragment.

5. A process according to claim 1, wherein said second analogue is an epitope mimic.

6. A process according to claim 1, wherein said target ligand is estradiol or a metabolite thereof, especially estrone-3-glucuronide (E3G).

7. A process according to claim 6, wherein said target ligand is E3G and said first analogue is estrone.

8. A process according to claim 7, wherein said second analogue is estriol-3glucuronide or estradiol-3-glucuronide.

9. The process of claim 2 wherein the affinity of the binding agent for said target ligand is at least about 10 times greater than its affinity for said first analogue.

10. The process of claim 2 wherein the affinity of the binding agent for said target ligand is at least about 100 times greater than its affinity for said first analogue.

11. A process according to claim 2, wherein the affinity of said specific binding agent for said target ligand is at least about 10 times greater than its affinity for said second analogue.